{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Quality of response: % Complete Response (CR) + Very Good Partial Remission (VGPR) to induction Dd-R as assessed using International Myeloma Working Group Response Definitions. Very Good Partial Remission (VGPR): Detectable serum and urine M component on immunofixation but not on electrophoresis or 90% or greater reduction in serum M protein with less than 100 mg/24 h of urinary M protein. Complete Remission (CR): The presence of less than 5% bone marrow plasmacytosis and the disappearance of all evidence of serum and urine M-components on electrophoresis as well as by immunofixation. In addition, soft tissue plasmacytoma must have disappeared.","groups":[{"description":"Induction Phase Followed by Maintenance Therapy.\n\nPatients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\\^2 intravenously on day 1 (reduced to 30 mg/m\\^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.\n\nAt the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.\n\nDd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description.","id":"OG000","title":"Induction and Maintenance Therapy"}],"paramType":"NUMBER","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Percentage of Participants With Very Good Partial Remission (VGPR) or Better","type":"PRIMARY","unitOfMeasure":"percentage of participants"}